We describe the updated Korean Society of Gynecologic Oncology (KSGO) practice guideline for the management of cervical cancer, version 5.1. The KSGO announced the fifth version of its clinical practice guidelines for the management of cervical cancer in March 2024. The selection of the key questions and the systematic reviews were based on data available up to December 2022. Between 2023 and 2024, substantial findings from large-scale clinical trials and new advancements in cervical cancer research remarkably emerged. Therefore, based on the existing version 5.0, we updated the guidelines with newly accumulated clinical data and added 4 new key questions reflecting the latest insights in the field of cervical cancer. For each question, recommendation was formulated with corresponding level of evidence and grade of recommendation, all established through expert consensus.

We describe the updated Korean Society of Gynecologic Oncology (KSGO) practice guideline for the management of cervical cancer, version 5.1. The KSGO announced the fifth version of its clinical practice guidelines for the management of cervical cancer in March 2024. The selection of the key questions and the systematic reviews were based on data available up to December 2022. Between 2023 and 2024, substantial findings from large-scale clinical trials and new advancements in cervical cancer research remarkably emerged. Therefore, based on the existing version 5.0, we updated the guidelines with newly accumulated clinical data and added 4 new key questions reflecting the latest insights in the field of cervical cancer. For each question, recommendation was formulated with corresponding level of evidence and grade of recommendation, all established through expert consensus.

We describe the updated Korean Society of Gynecologic Oncology (KSGO) practice guideline for the management of cervical cancer, version 5.1. The KSGO announced the fifth version of its clinical practice guidelines for the management of cervical cancer in March 2024. The selection of the key questions and the systematic reviews were based on data available up to December 2022. Between 2023 and 2024, substantial findings from large-scale clinical trials and new advancements in cervical cancer research remarkably emerged. Therefore, based on the existing version 5.0, we updated the guidelines with newly accumulated clinical data and added 4 new key questions reflecting the latest insights in the field of cervical cancer. For each question, recommendation was formulated with corresponding level of evidence and grade of recommendation, all established through expert consensus.

The study of human immunodeficiency virus (HIV) infection during pregnancy is of great significance because most women are first diagnosed with HIV during pregnancy. Similarly, it is equally important in cases where one or both partners are HIV-positive and wish to conceive. Since the first case of HIV was reported in the 1980s, antiviral drugs have been developed to prevent progression to acquired immunodeficiency syndrome (AIDS), which allows many AIDS patients to be asymptomatic or have only mild symptoms. This case shows that consecutive pregnancies and births are possible through proper antiretroviral therapy along with regular prenatal examinations in HIV-positive women.Rather than recommending contraception or expressing negative opinions about pregnancy in HIV-infected couples, active HIV treatment and prenatal care should be conducted to support a safe pregnancy and lower the chance of vertical HIV transmission. Recently, there has been a case report on successive childbirths of HIV-positive pregnant women who continued to receive antiretroviral therapy after their first childbirth at our hospital. Through this case, we report that safe delivery of HIV-infected mothers is possible, and further subsequent childbirths can be achieved with the use of appropriate antiretroviral therapy.

The study of human immunodeficiency virus (HIV) infection during pregnancy is of great significance because most women are first diagnosed with HIV during pregnancy. Similarly, it is equally important in cases where one or both partners are HIV-positive and wish to conceive. Since the first case of HIV was reported in the 1980s, antiviral drugs have been developed to prevent progression to acquired immunodeficiency syndrome (AIDS), which allows many AIDS patients to be asymptomatic or have only mild symptoms. This case shows that consecutive pregnancies and births are possible through proper antiretroviral therapy along with regular prenatal examinations in HIV-positive women.Rather than recommending contraception or expressing negative opinions about pregnancy in HIV-infected couples, active HIV treatment and prenatal care should be conducted to support a safe pregnancy and lower the chance of vertical HIV transmission. Recently, there has been a case report on successive childbirths of HIV-positive pregnant women who continued to receive antiretroviral therapy after their first childbirth at our hospital. Through this case, we report that safe delivery of HIV-infected mothers is possible, and further subsequent childbirths can be achieved with the use of appropriate antiretroviral therapy.

The study of human immunodeficiency virus (HIV) infection during pregnancy is of great significance because most women are first diagnosed with HIV during pregnancy. Similarly, it is equally important in cases where one or both partners are HIV-positive and wish to conceive. Since the first case of HIV was reported in the 1980s, antiviral drugs have been developed to prevent progression to acquired immunodeficiency syndrome (AIDS), which allows many AIDS patients to be asymptomatic or have only mild symptoms. This case shows that consecutive pregnancies and births are possible through proper antiretroviral therapy along with regular prenatal examinations in HIV-positive women.Rather than recommending contraception or expressing negative opinions about pregnancy in HIV-infected couples, active HIV treatment and prenatal care should be conducted to support a safe pregnancy and lower the chance of vertical HIV transmission. Recently, there has been a case report on successive childbirths of HIV-positive pregnant women who continued to receive antiretroviral therapy after their first childbirth at our hospital. Through this case, we report that safe delivery of HIV-infected mothers is possible, and further subsequent childbirths can be achieved with the use of appropriate antiretroviral therapy.

Background/Aims: Obesity has known to be a modifiable risk factor associated with worse outcomes in chronic kidney disease (CKD), but few studies have examined the impact of obesity on CKD incidence in the general population. The purpose of this study was to investigate the role of body mass index (BMI) and waist-to-hip ratio (WHR) as predictors of incident CKD and to evaluate the impact of weight reduction on CKD prevention. Methods: A total of 2,711 participants from a community-based cohort with normal renal function were prospectively analyzed. Among participants with obesity, we analyzed the change in WHR to evaluate the association of obesity reduction with CKD development. Results: During a mean follow-up of 11.03 ± 4.22 years, incident CKD occurred in 190 (7.0%) participants. In the fully adjusted multivariable Cox proportional hazard models, the risk of incident CKD increased with higher BMI (hazard ratio, 1.06; 95% confidence interval, 1.00–1.11; p = 0.033) and higher WHR (hazard ratio, 1.33; 95% confidence interval, 1.07–1.66; p = 0.009). In the Kaplan–Meier analysis, cumulative adverse renal events were significantly more common in the maintained obesity group than in the reduced obesity group (p = 0.001). Conclusions Both higher BMI and WHR were associated with development of CKD, but the magnitude of the effect of WHR was higher than that of BMI. Moreover, reducing obesity would be beneficial for renal prognosis.

This fifth revised version of the Korean Society of Gynecologic Oncology practice guidelines for the management of cervical cancer incorporates recent research findings and changes in treatment strategies based on version 4.0 released in 2020. Each key question was developed by focusing on recent notable insights and crucial contemporary issues in the field of cervical cancer. These questions were evaluated for their significance and impact on the current treatment and were finalized through voting by the development committee. The selected key questions were as follows: the efficacy and safety of immune checkpoint inhibitors as firstor second-line treatment for recurrent or metastatic cervical cancer; the oncologic safety of minimally invasive radical hysterectomy in early stage cervical cancer; the efficacy and safety of adjuvant systemic treatment after concurrent chemoradiotherapy in locally advanced cervical cancer; and the oncologic safety of sentinel lymph node mapping compared to pelvic lymph node dissection. The recommendations, directions, and strengths of this guideline were based on systematic reviews and meta-analyses, and were finally confirmed through public hearings and external reviews. In this study, we describe the revised practice guidelines for the management of cervical cancer.

This fifth revised version of the Korean Society of Gynecologic Oncology practice guidelines for the management of cervical cancer incorporates recent research findings and changes in treatment strategies based on version 4.0 released in 2020. Each key question was developed by focusing on recent notable insights and crucial contemporary issues in the field of cervical cancer. These questions were evaluated for their significance and impact on the current treatment and were finalized through voting by the development committee. The selected key questions were as follows: the efficacy and safety of immune checkpoint inhibitors as firstor second-line treatment for recurrent or metastatic cervical cancer; the oncologic safety of minimally invasive radical hysterectomy in early stage cervical cancer; the efficacy and safety of adjuvant systemic treatment after concurrent chemoradiotherapy in locally advanced cervical cancer; and the oncologic safety of sentinel lymph node mapping compared to pelvic lymph node dissection. The recommendations, directions, and strengths of this guideline were based on systematic reviews and meta-analyses, and were finally confirmed through public hearings and external reviews. In this study, we describe the revised practice guidelines for the management of cervical cancer.

The study of human immunodeficiency virus (HIV) infection during pregnancy is of great significance because most women are first diagnosed with HIV during pregnancy. Similarly, it is equally important in cases where one or both partners are HIV-positive and wish to conceive. Since the first case of HIV was reported in the 1980s, antiviral drugs have been developed to prevent progression to acquired immunodeficiency syndrome (AIDS), which allows many AIDS patients to be asymptomatic or have only mild symptoms. This case shows that consecutive pregnancies and births are possible through proper antiretroviral therapy along with regular prenatal examinations in HIV-positive women.Rather than recommending contraception or expressing negative opinions about pregnancy in HIV-infected couples, active HIV treatment and prenatal care should be conducted to support a safe pregnancy and lower the chance of vertical HIV transmission. Recently, there has been a case report on successive childbirths of HIV-positive pregnant women who continued to receive antiretroviral therapy after their first childbirth at our hospital. Through this case, we report that safe delivery of HIV-infected mothers is possible, and further subsequent childbirths can be achieved with the use of appropriate antiretroviral therapy.